IMPORTANT SAFETY INFORMATION
Contraindication

Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Drug Interactions

• Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.

• Dose modifications are recommended when using the following:
‐ Moderate or weak CYP3A4 inhibitors and inducers ‐ BCRP and/or P-gp only inhibitors

Dosage and Administration

• The recommended dose is 50 mg or 100 mg taken orally, as needed.

• If needed, a second dose may be administered at least 2 hours after the initial dose.

• The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.

• Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.

• Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

REFERENCES

1. Data on file. Allergan. 2. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2020. 3. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241. 4. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain from the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. 5. IQVIA RAPID NPA Weekly Audit. Weekly audit for acute migraine Rx: week of 12/4/2020. 6. Dodick DW, Goadsby PJ, Lu K, Jakata A, Szegedi A, Trugman JM. Ubrogepant achieves early pain relief for the acute treatment of migraine. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA. Poster P103. 7. Lipton RB, Ailani J, Hutchinson S, et al. Efficacy is maintained with long-term intermittent use of ubrogepant for the acute treatment of migraine. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA. Poster P135.

More
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindication

Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Drug Interactions

• Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.

• Dose modifications are recommended when using the following:
‐ Moderate or weak CYP3A4 inhibitors and inducers ‐ BCRP and/or P-gp only inhibitors

Dosage and Administration

• The recommended dose is 50 mg or 100 mg taken orally, as needed.

• If needed, a second dose may be administered at least 2 hours after the initial dose.

• The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.

• Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.

• Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

>